Skip to main content
Public beta This website is in public beta – please give your feedback.

Example clinical scenario

A seven-year-old boy presents with a fractured tibia after a fall off his scooter. He has had two previous long bone fractures with minimal trauma. His mother had multiple fractures as a child but has had none since. On examination, his height is two standard deviations (2SD) below the mean (on the 2nd centile) and he has joint hypermobility.

When to consider genomic testing

You should consider genomic testing if your patient has features suggestive of osteogenesis imperfecta (OI). In adults, testing is only routinely recommended if it will impact on reproductive choices. In general, testing should only be performed if it will impact clinical management.

Features of OI may include:

  • fractures (associated with minimal or no trauma);
  • short stature;
  • bowing of long bones;
  • blue sclera;
  • abnormal dentition (dentinogenesis imperfecta);
  • hypermobility; and
  • hearing loss (post-pubertal).

Radiological features include:

  • fractures;
  • wormian bones;
  • ‘codfish’ vertebrae;
  • low bone mass; and
  • protrusio acetabuli.

What do you need to do?

  • Consult the National Genomic Test Directory. From here you can access the rare and inherited disease eligibility criteria for information about individual tests and their associated eligibility criteria. You can also access a spreadsheet of all available tests.
  • For information about the genes that are included on different gene panels, see the NHS Genomic Medicine Service (GMS) Signed Off Panels Resource.
  • Decide which of the panels best suits the needs of your patient or family.
  • If you clinically suspect OI in a family, the correct test to order is:
  • If a member of the family already has a known OI-related gene causative variant, cascade testing can be carried out to identify other affected individuals. Testing relatives when the molecular basis is confirmed in the family may not be needed unless there is a clear rationale for doing so – for example, where the clinical diagnosis in the relative is in doubt, or if testing the relative will lead to a clear benefit in management, such as eligibility for a clinical trial. In this situation, the laboratory will test for the known familial variant only. First-degree relatives may be eligible for genomic counselling, at which point subsequent testing (R240 Diagnostic testing for known variant(s)) can be arranged.
  • If you feel there are other likely diagnoses for bone fragility, or if R102 testing is negative, you may wish to consider the following tests:
    • R104 Skeletal dysplasia: This should be considered if clinical features are indicative of a likely monogenic skeletal dysplasia. See Presentation: Child with suspected skeletal dysplasia.
    • R28 Congenital malformation and dysmorphism syndromes – microarray only, or R27 Paediatric disorders: If your patient has short stature and congenital malformations and/or dysmorphism suggestive of an underlying monogenic disorder, and targeted genomic testing is not possible. Where possible, the chromosomal disorder suspected should be specified on the test request form.
    • Skin biopsy for collagen analysis can be useful if genomic testing is negative and the diagnosis is still unclear.
  • For tests that do not include whole genome sequencing (WGS), including R102 and R28:
    • you can use your local Genomic Laboratory Hub (GLH) test order and consent (record of discussion) forms; and
    • parental samples may be needed for interpretation of the child’s result. Parental samples can be taken alongside that of the child, and their DNA stored, or can be requested at a later date if needed.
  • For tests that are undertaken using WGS, including R104 and R27, you will need to:
  • R27 is an amalgamation of more than 10 panels of genes known to be associated with a broad range of paediatric developmental disorders. It may now be ordered directly by paediatricians, though a discussion with clinical genetics services may be beneficial. Requesting R104 currently requires clinical genetics approval.
  • Most tests are DNA based, and an EDTA sample (typically a purple-topped tube) is required. There are a few tests for which a different type of tube is used; see Samples for genomic testing in rare disease.
  • If you are discussing genomics concepts with your patients, you may find it helpful to use the visual communication aids for genomics conversations.

Information about patient eligibility and test indications was correct at the time of writing. When requesting a test, please refer to the National Genomic Test Directory to confirm the right test for your patient.

Resources

For clinicians

↑ Back to top
  • Last reviewed: 25/11/2025
  • Next review due: 25/11/2026
  • Authors: Dr Ataf Sabir
  • Reviewers: Dr Danielle Bogue, Dr Amy Frost, Dr Emile Hendriks